STOCK TITAN

[8-K] SUNCOKE ENERGY INC Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Clearside Biomedical, Inc. (CLSD) has issued a Definitive Proxy Statement (DEF 14A) for a Special Meeting on 29 Aug 2025. The Board is asking holders of the 78.5 m outstanding shares (record date: 28 Jul 2025) to approve a single corporate action:

  • Proposal 1 – Reverse Stock Split & Authorized Share Reduction: authorises the Board, at its discretion within 12 months, to combine shares in any ratio from 1-for-5 to 1-for-15 and simultaneously cut authorised common shares proportionately from the current 400 m down to 80 m–26.7 m, preserving par value ($0.001).

Rationale: CLSD has been out of compliance with Nasdaq’s $1.00 minimum bid price since 7 Feb 2025 and expects delisting notice after 6 Aug 2025. Management believes a higher share price following the reverse split is the most practical path to regain compliance and maintain Nasdaq Global Market listing, thereby protecting liquidity and financing options.

Voting mechanics: Proposal passes with a simple majority of votes cast; because it is deemed “routine” by NYSE rules, brokers may vote uninstructed street-name shares. No broker non-votes are expected. Quorum is >50% of outstanding shares (≥39.26 m). No dissenters’ rights apply.

Effects: Share counts, option pools and ATM capacity will shrink proportionally; fractional shares will be cashed out at the 5-day average market price. Ownership percentages and rights remain unchanged. The Board may abandon or defer the split if price compliance is regained independently.

Clearside Biomedical, Inc. (CLSD) ha emesso una Dichiarazione Definitiva di Procura (DEF 14A) per una Assemblea Straordinaria il 29 agosto 2025. Il Consiglio chiede ai detentori delle 78,5 milioni di azioni in circolazione (data di registrazione: 28 luglio 2025) di approvare una singola azione societaria:

  • Proposta 1 – Raggruppamento azionario inverso e riduzione delle azioni autorizzate: autorizza il Consiglio, a sua discrezione entro 12 mesi, a combinare le azioni in un rapporto da 1 a 5 fino a 1 a 15 e contemporaneamente ridurre proporzionalmente le azioni ordinarie autorizzate dall'attuale 400 milioni a un intervallo tra 80 milioni e 26,7 milioni, mantenendo il valore nominale ($0,001).

Motivazione: CLSD non rispetta il prezzo minimo di offerta di $1,00 richiesto da Nasdaq dal 7 febbraio 2025 e prevede una notifica di esclusione dopo il 6 agosto 2025. La direzione ritiene che un prezzo azionario più alto dopo il raggruppamento inverso sia la soluzione più pratica per tornare a conformarsi e mantenere la quotazione sul Nasdaq Global Market, proteggendo così liquidità e opzioni di finanziamento.

Modalità di voto: La proposta viene approvata con la maggioranza semplice dei voti espressi; poiché è considerata "ordinaria" secondo le regole NYSE, i broker possono votare per le azioni street-name senza istruzioni. Non sono previsti voti non espressi dai broker. Il quorum è superiore al 50% delle azioni in circolazione (≥39,26 milioni). Non si applicano diritti di opposizione.

Effetti: Il numero di azioni, i pool di opzioni e la capacità ATM diminuiranno proporzionalmente; le azioni frazionarie saranno liquidate al prezzo medio di mercato su 5 giorni. Le percentuali di proprietà e i diritti rimangono invariati. Il Consiglio può abbandonare o rinviare il raggruppamento se il prezzo torna a rispettare i requisiti in modo autonomo.

Clearside Biomedical, Inc. (CLSD) ha emitido una Declaración Definitiva de Poder (DEF 14A) para una Junta Especial el 29 de agosto de 2025. La Junta solicita a los titulares de las 78.5 millones de acciones en circulación (fecha de registro: 28 de julio de 2025) aprobar una única acción corporativa:

  • Propuesta 1 – Consolidación inversa de acciones y reducción de acciones autorizadas: autoriza a la Junta, a su discreción dentro de 12 meses, a combinar las acciones en cualquier proporción desde 1 por 5 hasta 1 por 15 y simultáneamente reducir proporcionalmente las acciones comunes autorizadas de las actuales 400 millones a un rango de 80 millones a 26.7 millones, preservando el valor nominal ($0.001).

Justificación: CLSD ha incumplido con el precio mínimo de oferta de Nasdaq de $1.00 desde el 7 de febrero de 2025 y espera una notificación de exclusión después del 6 de agosto de 2025. La gerencia cree que un precio de acción más alto tras la consolidación inversa es la vía más práctica para recuperar el cumplimiento y mantener la cotización en Nasdaq Global Market, protegiendo así la liquidez y las opciones de financiamiento.

Mecánica de votación: La propuesta se aprueba con mayoría simple de los votos emitidos; dado que se considera "rutinaria" según las normas de NYSE, los corredores pueden votar acciones street-name sin instrucciones. No se esperan votos no emitidos por corredores. El quórum es >50% de las acciones en circulación (≥39.26 millones). No aplican derechos de disidentes.

Efectos: El número de acciones, los pools de opciones y la capacidad ATM se reducirán proporcionalmente; las acciones fraccionarias se pagarán en efectivo al precio promedio de mercado de 5 días. Los porcentajes de propiedad y derechos permanecen sin cambios. La Junta puede abandonar o aplazar la consolidación si se recupera el cumplimiento del precio de forma independiente.

Clearside Biomedical, Inc. (CLSD)는 2025년 8월 29일 특별 주주총회를 위한 최종 위임장 명세서(DEF 14A)를 발행했습니다. 이사회는 78.5백만 주의 발행 주식 보유자(기준일: 2025년 7월 28일)에게 단일 회사 조치를 승인해 줄 것을 요청하고 있습니다:

  • 제안 1 – 주식 병합 역분할 및 승인 주식 수 감소: 이사회가 재량에 따라 12개월 내에 주식을 1대 5에서 1대 15 비율로 병합하고 동시에 승인된 보통주 수를 현재 4억 주에서 8천만 주~2,670만 주로 비례 축소하며 액면가($0.001)를 유지하도록 승인합니다.

배경: CLSD는 2025년 2월 7일부터 나스닥의 최소 입찰 가격 $1.00 미달 상태이며 2025년 8월 6일 이후 상장폐지 통지를 받을 것으로 예상됩니다. 경영진은 역분할 후 주가 상승이 규정 준수를 회복하고 나스닥 글로벌 마켓 상장을 유지하는 가장 현실적인 방법이라고 판단하여 유동성과 자금 조달 옵션을 보호하려고 합니다.

투표 방식: 제안은 투표된 표의 단순 과반수로 통과됩니다; NYSE 규정에 따라 "일상적"으로 간주되어 중개인은 지시 없는 스트리트 네임 주식에 대해 투표할 수 있습니다. 중개인 미투표는 예상되지 않습니다. 정족수는 발행 주식의 50% 초과(≥3,926만 주)입니다. 이의 제기 권리는 적용되지 않습니다.

영향: 주식 수, 옵션 풀 및 ATM 용량이 비례하여 축소되며, 소수 주식은 5일 평균 시장 가격으로 현금화됩니다. 소유 비율과 권리는 변하지 않습니다. 주가가 독자적으로 규정 준수를 회복하면 이사회가 병합을 포기하거나 연기할 수 있습니다.

Clearside Biomedical, Inc. (CLSD) a publié une Déclaration de Procuration Définitive (DEF 14A) pour une Assemblée Spéciale le 29 août 2025. Le Conseil d'administration demande aux détenteurs des 78,5 millions d'actions en circulation (date d'enregistrement : 28 juillet 2025) d'approuver une action unique de la société :

  • Proposition 1 – Regroupement inversé d'actions et réduction des actions autorisées : autorise le Conseil, à sa discrétion dans un délai de 12 mois, à regrouper les actions selon un ratio compris entre 1 pour 5 et 1 pour 15 et à réduire simultanément les actions ordinaires autorisées de 400 millions à une fourchette de 80 millions à 26,7 millions, en préservant la valeur nominale (0,001 $).

Justification : CLSD est en non-conformité avec le prix minimum d'offre Nasdaq de 1,00 $ depuis le 7 février 2025 et s'attend à un avis de radiation après le 6 août 2025. La direction estime qu'un prix de l'action plus élevé suite au regroupement inversé est la solution la plus pratique pour retrouver la conformité et maintenir la cotation sur le Nasdaq Global Market, protégeant ainsi la liquidité et les options de financement.

Mécanique de vote : La proposition est adoptée à la majorité simple des votes exprimés ; considérée comme « routinière » selon les règles du NYSE, les courtiers peuvent voter pour les actions street-name sans instructions. Aucun vote non exprimé par les courtiers n'est attendu. Le quorum est supérieur à 50 % des actions en circulation (≥39,26 millions). Les droits des dissidents ne s'appliquent pas.

Effets : Le nombre d'actions, les pools d'options et la capacité ATM diminueront proportionnellement ; les actions fractionnaires seront rachetées au prix moyen du marché sur 5 jours. Les pourcentages de propriété et les droits restent inchangés. Le Conseil peut abandonner ou reporter le regroupement si la conformité des prix est rétablie de manière autonome.

Clearside Biomedical, Inc. (CLSD) hat eine Endgültige Vollmachtsmitteilung (DEF 14A) für eine Sonderversammlung am 29. August 2025 herausgegeben. Der Vorstand bittet die Inhaber der 78,5 Mio. ausstehenden Aktien (Stichtag: 28. Juli 2025), einer einzigen Unternehmensmaßnahme zuzustimmen:

  • Vorschlag 1 – Aktiensplit rückwärts & Reduzierung der genehmigten Aktien: Ermächtigt den Vorstand, nach eigenem Ermessen innerhalb von 12 Monaten Aktien im Verhältnis von 1 zu 5 bis 1 zu 15 zusammenzulegen und gleichzeitig die genehmigten Stammaktien proportional von derzeit 400 Mio. auf 80 Mio. bis 26,7 Mio. zu reduzieren, wobei der Nennwert ($0,001) erhalten bleibt.

Begründung: CLSD erfüllt seit dem 7. Februar 2025 nicht mehr die Nasdaq-Mindestgebotspreisvorgabe von 1,00 $ und erwartet nach dem 6. August 2025 eine Delisting-Benachrichtigung. Das Management ist der Ansicht, dass ein höherer Aktienkurs nach dem Reverse Split der praktischste Weg ist, die Compliance wiederherzustellen und die Notierung am Nasdaq Global Market beizubehalten, wodurch Liquidität und Finanzierungsmöglichkeiten geschützt werden.

Abstimmungsmodalitäten: Der Vorschlag wird mit einfacher Mehrheit der abgegebenen Stimmen angenommen; da er gemäß NYSE-Regeln als „routinemäßig“ gilt, dürfen Broker uninstruierte Street-Name-Aktien abstimmen. Es werden keine Broker-Non-Votes erwartet. Das Quorum beträgt >50 % der ausstehenden Aktien (≥39,26 Mio.). Es gelten keine Minderheitenrechte.

Auswirkungen: Aktienanzahl, Optionspools und ATM-Kapazität schrumpfen proportional; Bruchstücke werden zum 5-Tage-Durchschnittskurs ausgezahlt. Eigentumsanteile und Rechte bleiben unverändert. Der Vorstand kann den Split abbrechen oder verschieben, falls die Kursanforderungen eigenständig wieder erfüllt werden.

Positive
  • Maintains Nasdaq listing: Reverse split is the quickest route to regain the $1.00 bid price, protecting liquidity and institutional visibility.
  • Flexible ratio range (1-5 to 1-15) allows the Board to tailor the split to market conditions, increasing chance of compliance.
  • Authorized share cut alleviates concerns over excessive unissued shares post-split, limiting potential future dilution.
Negative
  • Liquidity risk: Fewer outstanding shares may widen spreads and reduce trading volume.
  • No guarantee of sustained price: Historical data show many reverse-split stocks drift back below compliance levels without operational improvements.
  • Odd-lot costs: Holders ending with <100 shares may face higher brokerage fees and selling difficulties.

Insights

TL;DR: Board seeks flexible 1-for-5–15 reverse split to avert Nasdaq delisting; modestly positive if it restores bid price, neutral otherwise.

The filing is defensive rather than transformative. A reverse split is a common cure for sub-$1 stocks; it neither improves fundamentals nor raises capital but preserves market access. Flexibility across 11 ratios lets the Board match prevailing prices and minimise post-split volatility. Because authorisation covers only 12 months and may be abandoned, dilution risk is limited to micro-rounding of fractional shares. The move could attract institutions barred from penny stocks and keep CLSD eligible for index inclusion, yet liquidity may fall as the float contracts and odd-lots rise. Success hinges on sustaining a >$1.00 price; history shows reverse splits often fade if unaccompanied by operating catalysts. Overall impact viewed as guardedly positive but not value-creating.

TL;DR: Proposal follows best-practice—single agenda item, proportional auth-share cut, routine vote; governance risks appear low.

The Board’s design addresses shareholder dilution concerns by pairing the split with an authorised share reduction, avoiding an inflated share reserve that could facilitate future issuances without approval. Voting thresholds are standard and broker discretion ensures likely passage. Cash-out for fractional shares is at a transparent 5-day VWAP, limiting dispute risk. Anti-takeover effects are acknowledged but minimal given reduced authorised pool. No insider entrenchment signals emerge; executives collectively own only 6.7 % pre-split. From a governance lens, the measure is procedurally sound and shareholder-friendly.

Clearside Biomedical, Inc. (CLSD) ha emesso una Dichiarazione Definitiva di Procura (DEF 14A) per una Assemblea Straordinaria il 29 agosto 2025. Il Consiglio chiede ai detentori delle 78,5 milioni di azioni in circolazione (data di registrazione: 28 luglio 2025) di approvare una singola azione societaria:

  • Proposta 1 – Raggruppamento azionario inverso e riduzione delle azioni autorizzate: autorizza il Consiglio, a sua discrezione entro 12 mesi, a combinare le azioni in un rapporto da 1 a 5 fino a 1 a 15 e contemporaneamente ridurre proporzionalmente le azioni ordinarie autorizzate dall'attuale 400 milioni a un intervallo tra 80 milioni e 26,7 milioni, mantenendo il valore nominale ($0,001).

Motivazione: CLSD non rispetta il prezzo minimo di offerta di $1,00 richiesto da Nasdaq dal 7 febbraio 2025 e prevede una notifica di esclusione dopo il 6 agosto 2025. La direzione ritiene che un prezzo azionario più alto dopo il raggruppamento inverso sia la soluzione più pratica per tornare a conformarsi e mantenere la quotazione sul Nasdaq Global Market, proteggendo così liquidità e opzioni di finanziamento.

Modalità di voto: La proposta viene approvata con la maggioranza semplice dei voti espressi; poiché è considerata "ordinaria" secondo le regole NYSE, i broker possono votare per le azioni street-name senza istruzioni. Non sono previsti voti non espressi dai broker. Il quorum è superiore al 50% delle azioni in circolazione (≥39,26 milioni). Non si applicano diritti di opposizione.

Effetti: Il numero di azioni, i pool di opzioni e la capacità ATM diminuiranno proporzionalmente; le azioni frazionarie saranno liquidate al prezzo medio di mercato su 5 giorni. Le percentuali di proprietà e i diritti rimangono invariati. Il Consiglio può abbandonare o rinviare il raggruppamento se il prezzo torna a rispettare i requisiti in modo autonomo.

Clearside Biomedical, Inc. (CLSD) ha emitido una Declaración Definitiva de Poder (DEF 14A) para una Junta Especial el 29 de agosto de 2025. La Junta solicita a los titulares de las 78.5 millones de acciones en circulación (fecha de registro: 28 de julio de 2025) aprobar una única acción corporativa:

  • Propuesta 1 – Consolidación inversa de acciones y reducción de acciones autorizadas: autoriza a la Junta, a su discreción dentro de 12 meses, a combinar las acciones en cualquier proporción desde 1 por 5 hasta 1 por 15 y simultáneamente reducir proporcionalmente las acciones comunes autorizadas de las actuales 400 millones a un rango de 80 millones a 26.7 millones, preservando el valor nominal ($0.001).

Justificación: CLSD ha incumplido con el precio mínimo de oferta de Nasdaq de $1.00 desde el 7 de febrero de 2025 y espera una notificación de exclusión después del 6 de agosto de 2025. La gerencia cree que un precio de acción más alto tras la consolidación inversa es la vía más práctica para recuperar el cumplimiento y mantener la cotización en Nasdaq Global Market, protegiendo así la liquidez y las opciones de financiamiento.

Mecánica de votación: La propuesta se aprueba con mayoría simple de los votos emitidos; dado que se considera "rutinaria" según las normas de NYSE, los corredores pueden votar acciones street-name sin instrucciones. No se esperan votos no emitidos por corredores. El quórum es >50% de las acciones en circulación (≥39.26 millones). No aplican derechos de disidentes.

Efectos: El número de acciones, los pools de opciones y la capacidad ATM se reducirán proporcionalmente; las acciones fraccionarias se pagarán en efectivo al precio promedio de mercado de 5 días. Los porcentajes de propiedad y derechos permanecen sin cambios. La Junta puede abandonar o aplazar la consolidación si se recupera el cumplimiento del precio de forma independiente.

Clearside Biomedical, Inc. (CLSD)는 2025년 8월 29일 특별 주주총회를 위한 최종 위임장 명세서(DEF 14A)를 발행했습니다. 이사회는 78.5백만 주의 발행 주식 보유자(기준일: 2025년 7월 28일)에게 단일 회사 조치를 승인해 줄 것을 요청하고 있습니다:

  • 제안 1 – 주식 병합 역분할 및 승인 주식 수 감소: 이사회가 재량에 따라 12개월 내에 주식을 1대 5에서 1대 15 비율로 병합하고 동시에 승인된 보통주 수를 현재 4억 주에서 8천만 주~2,670만 주로 비례 축소하며 액면가($0.001)를 유지하도록 승인합니다.

배경: CLSD는 2025년 2월 7일부터 나스닥의 최소 입찰 가격 $1.00 미달 상태이며 2025년 8월 6일 이후 상장폐지 통지를 받을 것으로 예상됩니다. 경영진은 역분할 후 주가 상승이 규정 준수를 회복하고 나스닥 글로벌 마켓 상장을 유지하는 가장 현실적인 방법이라고 판단하여 유동성과 자금 조달 옵션을 보호하려고 합니다.

투표 방식: 제안은 투표된 표의 단순 과반수로 통과됩니다; NYSE 규정에 따라 "일상적"으로 간주되어 중개인은 지시 없는 스트리트 네임 주식에 대해 투표할 수 있습니다. 중개인 미투표는 예상되지 않습니다. 정족수는 발행 주식의 50% 초과(≥3,926만 주)입니다. 이의 제기 권리는 적용되지 않습니다.

영향: 주식 수, 옵션 풀 및 ATM 용량이 비례하여 축소되며, 소수 주식은 5일 평균 시장 가격으로 현금화됩니다. 소유 비율과 권리는 변하지 않습니다. 주가가 독자적으로 규정 준수를 회복하면 이사회가 병합을 포기하거나 연기할 수 있습니다.

Clearside Biomedical, Inc. (CLSD) a publié une Déclaration de Procuration Définitive (DEF 14A) pour une Assemblée Spéciale le 29 août 2025. Le Conseil d'administration demande aux détenteurs des 78,5 millions d'actions en circulation (date d'enregistrement : 28 juillet 2025) d'approuver une action unique de la société :

  • Proposition 1 – Regroupement inversé d'actions et réduction des actions autorisées : autorise le Conseil, à sa discrétion dans un délai de 12 mois, à regrouper les actions selon un ratio compris entre 1 pour 5 et 1 pour 15 et à réduire simultanément les actions ordinaires autorisées de 400 millions à une fourchette de 80 millions à 26,7 millions, en préservant la valeur nominale (0,001 $).

Justification : CLSD est en non-conformité avec le prix minimum d'offre Nasdaq de 1,00 $ depuis le 7 février 2025 et s'attend à un avis de radiation après le 6 août 2025. La direction estime qu'un prix de l'action plus élevé suite au regroupement inversé est la solution la plus pratique pour retrouver la conformité et maintenir la cotation sur le Nasdaq Global Market, protégeant ainsi la liquidité et les options de financement.

Mécanique de vote : La proposition est adoptée à la majorité simple des votes exprimés ; considérée comme « routinière » selon les règles du NYSE, les courtiers peuvent voter pour les actions street-name sans instructions. Aucun vote non exprimé par les courtiers n'est attendu. Le quorum est supérieur à 50 % des actions en circulation (≥39,26 millions). Les droits des dissidents ne s'appliquent pas.

Effets : Le nombre d'actions, les pools d'options et la capacité ATM diminueront proportionnellement ; les actions fractionnaires seront rachetées au prix moyen du marché sur 5 jours. Les pourcentages de propriété et les droits restent inchangés. Le Conseil peut abandonner ou reporter le regroupement si la conformité des prix est rétablie de manière autonome.

Clearside Biomedical, Inc. (CLSD) hat eine Endgültige Vollmachtsmitteilung (DEF 14A) für eine Sonderversammlung am 29. August 2025 herausgegeben. Der Vorstand bittet die Inhaber der 78,5 Mio. ausstehenden Aktien (Stichtag: 28. Juli 2025), einer einzigen Unternehmensmaßnahme zuzustimmen:

  • Vorschlag 1 – Aktiensplit rückwärts & Reduzierung der genehmigten Aktien: Ermächtigt den Vorstand, nach eigenem Ermessen innerhalb von 12 Monaten Aktien im Verhältnis von 1 zu 5 bis 1 zu 15 zusammenzulegen und gleichzeitig die genehmigten Stammaktien proportional von derzeit 400 Mio. auf 80 Mio. bis 26,7 Mio. zu reduzieren, wobei der Nennwert ($0,001) erhalten bleibt.

Begründung: CLSD erfüllt seit dem 7. Februar 2025 nicht mehr die Nasdaq-Mindestgebotspreisvorgabe von 1,00 $ und erwartet nach dem 6. August 2025 eine Delisting-Benachrichtigung. Das Management ist der Ansicht, dass ein höherer Aktienkurs nach dem Reverse Split der praktischste Weg ist, die Compliance wiederherzustellen und die Notierung am Nasdaq Global Market beizubehalten, wodurch Liquidität und Finanzierungsmöglichkeiten geschützt werden.

Abstimmungsmodalitäten: Der Vorschlag wird mit einfacher Mehrheit der abgegebenen Stimmen angenommen; da er gemäß NYSE-Regeln als „routinemäßig“ gilt, dürfen Broker uninstruierte Street-Name-Aktien abstimmen. Es werden keine Broker-Non-Votes erwartet. Das Quorum beträgt >50 % der ausstehenden Aktien (≥39,26 Mio.). Es gelten keine Minderheitenrechte.

Auswirkungen: Aktienanzahl, Optionspools und ATM-Kapazität schrumpfen proportional; Bruchstücke werden zum 5-Tage-Durchschnittskurs ausgezahlt. Eigentumsanteile und Rechte bleiben unverändert. Der Vorstand kann den Split abbrechen oder verschieben, falls die Kursanforderungen eigenständig wieder erfüllt werden.

0001514705FALSE00015147052025-08-012025-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________

FORM 8-K
___________________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

August 1, 2025
Date of Report (date of earliest event reported)
___________________________________

SunCoke Energy, Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
(State of Incorporation)
001-35243
(Commission File Number)
90-0640593
(IRS Employer Identification Number)
1011 Warrenville Road, Suite 600
Lisle,IL60532
(Address of principal executive offices and zip code)
(630)824-1000
(Registrant's telephone number, including area code)
___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.01SXCNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.01 - Completion of Acquisition or Disposition of Assets.

On August 1, 2025, SunCoke Energy, Inc. (the “Company”) completed its previously announced acquisition of Flame Aggregator, LLC, a Delaware limited liability company (“Flame Aggregator”), which, together with its subsidiaries, operates as Phoenix Global, a privately held provider of mission-critical mill services to major steel producing companies.

The acquisition was consummated pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) by and among Sun Coal & Coke LLC, a Delaware limited liability company (“Sun Coal & Coke”) and a direct, wholly owned subsidiary of the Company, Metal Services Acquisition, LLC, a Delaware limited liability company and wholly owned subsidiary of Sun Coal & Coke (“Merger Sub”), Flame Aggregator, and Shareholder Representative Services LLC, a Colorado limited liability company, in its capacity as the representative, agent, and attorney-in-fact for the unitholders of Flame Aggregator.

As contemplated by the Merger Agreement, Merger Sub merged with and into Flame Aggregator, with Flame Aggregator continuing as the surviving entity and a wholly owned subsidiary of the Company (the “Merger”). Pursuant to the Merger Agreement, Flame Aggregator’s unitholders received cash consideration in an amount equal to $325 million, subject to certain customary adjustments for net working capital, cash and cash equivalents, indebtedness and unpaid transaction expenses, all as set forth in the Merger Agreement. The Company funded the transaction with cash on-hand and revolving credit facility borrowing.

The foregoing general description of the Merger and Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 28, 2025.

Item 7.01 - Regulation FD Disclosure.

On August 4, 2025, the Company issued a press release announcing the completion of the Merger. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and is not deemed to be “filed” with the SEC for the purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference to this Current Report on Form 8-K in such filing.

Item 9.01 - Financial Statements and Exhibits.

(a): Financial statements of businesses acquired.

To the extent required, as permitted by Item 9.01(a)(3) of Form 8-K, the Company will provide the financial statements required by Item 9.01(a) of Form 8-K by amendment to this Current Report on Form 8-K no later than 71 days following the date on which this Current Report on Form 8-K is required to be filed.

(b): Pro forma financial information.

To the extent required, as permitted by Item 9.01(a)(3) of Form 8-K, the Company will provide the pro forma financial statements required by Item 9.01(b) of Form 8-K will be filed by amendment to this Current Report on Form 8-K no later than 71 days following the date on which this Current Report on Form 8-K is required to be filed.

(d): Exhibits.

The information in the Exhibit Index of this Current Report on Form 8-K is incorporated into this item 9.01(d) by reference.

Exhibit No.
99.1
SunCoke Energy, Inc. Press Release, dated August 4, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)






Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Sun Coal & Coke’s proposed acquisition of Flame Aggregator. Forward-looking statements may be identified by words such as “will,” “expect,” “outlook,” “guidance,” “project,” “anticipate,” “plan,” “estimate,” “target,” “believe,” “would,” “could,” “may,” “continue,” “possible,” “potential,” “should” and other similar words and expressions, though not all forward-looking statements use these words or expressions. These forward-looking statements are based on Company management’s current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to important factors discussed in Part I, Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as any such factors may be updated from time to time in the Company’s other filings with the SEC, including without limitation, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, accessible on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 4th day of August, 2025.


SUNCOKE ENERGY, INC.
By:
/s/ Mark W. Marinko
Name:
Mark W. Marinko
Title:
Senior Vice President and Chief Financial Officer



FAQ

Why does CLSD want a reverse stock split?

To raise its share price above Nasdaq’s $1.00 minimum bid rule and avoid delisting, which could impair liquidity and financing.

What split ratios are being proposed for Clearside Biomedical (CLSD)?

The Board may select any ratio from 1-for-5 up to 1-for-15, executing one split within 12 months or not at all.

Will the number of authorised CLSD shares change?

Yes. Authorised common shares will drop proportionally from 400 m to between 80 m and 26.7 m, matching the chosen split ratio.

How will fractional shares be handled after the reverse split?

Fractional entitlements will be cashed out at the 5-day average closing price preceding the effective date; no fractional shares will be issued.

What vote is required for Proposal 1 to pass at the August 29, 2025 meeting?

A simple majority of votes cast is sufficient; brokers may vote uninstructed street-name shares because the item is deemed routine.

When is the record date for voting on the CLSD special meeting?

Shareholders of record as of 28 July 2025 are entitled to vote the 78,510,318 outstanding shares.
Suncoke Energy Inc

NYSE:SXC

SXC Rankings

SXC Latest News

SXC Latest SEC Filings

SXC Stock Data

612.13M
83.92M
0.87%
96.81%
4.88%
Coking Coal
Steel Works, Blast Furnaces & Rolling Mills (coke Ovens)
Link
United States
LISLE